The Asco Post

Highlights of an ESH–iCMLf Satellite Symposium – Monitoring, Treatment Resistance, and Treatment Failure in Chronic Myeloid Leukemia: Breaking Barriers to Improved Outcomes and Looking Forward to a Cure

This activity is eligible for credit through November 15, 2013. After this date, this activity will expire and no further credit will be awarded.

Expected time to complete this activity as designed: 60 minutes

The content of this supplement, Highlights of an ESH–iCMLf Satellite Symposium – Monitoring, Treatment Resistance, and Treatment Failure in Chronic Myeloid Leukemia: Breaking Barriers to Improved Outcomes and Looking Forward to a Cure, is a component of an online CME activity accessible at the following links:

To obtain CME credit, click here: http://forms.medicaled.com/ascopostcme

To obtain CNE credit, click here: http://forms.medicaled.com/ascopostcne

View the digital edition here.

CE Activity Instructions

November 15, 2012, Volume 3, Issue 17, Supplement

*Corresponding author, MediCom Worldwide, Inc, 101 Washington Street, Morrisville, PA 19067, e-mail: gtombler@medicaled.com Activity Release Date: November 15, 2012Period of Validity: November 15, 2013 Program Overview This activity presents highlights from a satellite symposium held in conju...

Read More

Introduction

November 15, 2012, Volume 3, Issue 17, Supplement

This supplement to The ASCO Post highlights the proceedings of a satellite symposium that was presented as a case-based roundtable discussion titled, Monitoring, Treatment Resistance, and Treatment Failure in Chronic Myeloid Leukemia: Breaking Barriers to Improved Outcomes and Looking Forward to ...

Read More

Treatment Goals, Molecular Monitoring, and the Role and Use of Guideline Recommendations

November 15, 2012, Volume 3, Issue 17, Supplement

The importance of achieving a certain level of response with imatinib (Gleevec) by 3 months in patients with chronic myeloid leukemia (CML) had previously been established in the IRIS (International Randomized Study of Interferon and STI571) trial.1 Analysis of data from this trial showed that pa...

Read More

Beyond Molecular Monitoring: Cytogenetic Testing and Mutational Analysis in Chronic Myeloid Leukemia

November 15, 2012, Volume 3, Issue 17, Supplement

Cytogenetic analysis remains an important component of patient monitoring until a complete cytogenetic response is achieved. In addition, the ability of conventional cytogenetics to identify additional chromosomal abnormalities not detected by fluorescence in situ hybridization is noteworthy. Jor...

Read More

Defining and Recognizing the Causes of Imatinib Resistance and the Importance of Adherence

November 15, 2012, Volume 3, Issue 17, Supplement

Imatinib (Gleevec) is a highly effective therapy for the majority of patients with chronic myeloid leukemia (CML). In the IRIS study, only 30% of patients could be considered to have failed imatinib treatment after 6 years.1 However, these 30% of patients are a substantial minority. John Goldman,...

Read More

Managing Treatment Failure in Chronic Myeloid Leukemia

November 15, 2012, Volume 3, Issue 17, Supplement

As John Goldman, DM, FRCP, FRCPath, FMedSci, discussed earlier, a substantial minority of patients with chronic myeloid leukemia (CML) experience treatment failure. Jorge Cortes, MD, of The University of Texas MD Anderson Cancer Center, introduced this session with two patient cases to illustrate...

Read More

Defining a Cure for Chronic Myeloid Leukemia and Strategies to Achieve this Goal

November 15, 2012, Volume 3, Issue 17, Supplement

In chronic myeloid leukemia (CML), continued long-term therapy that prevents both progression to accelerated-phase disease and the emergence of resistance may be thought of as an “operational” or “functional” cure. However, long-term disease control without the requirement for continuous treatmen...

Read More
/
More on Twitter